Acurx Pharmaceuticals (ACXP) Competitors $0.47 -0.03 (-5.21%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$0.47 0.00 (-0.85%) As of 07/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. PLUR, PRLD, MURA, ATNM, SCLX, GRCE, XCUR, ACRV, PEPG, and STTKShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), Exicure (XCUR), Acrivon Therapeutics (ACRV), PepGen (PEPG), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Pluri Prelude Therapeutics Mural Oncology Actinium Pharmaceuticals Scilex Grace Therapeutics Exicure Acrivon Therapeutics PepGen Shattuck Labs Pluri (NASDAQ:PLUR) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment. Which has stronger valuation & earnings, PLUR or ACXP? Acurx Pharmaceuticals has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K125.99-$20.89M-$5.53-0.96Acurx PharmaceuticalsN/AN/A-$14.10M-$0.70-0.68 Do analysts recommend PLUR or ACXP? Pluri currently has a consensus price target of $12.00, indicating a potential upside of 125.99%. Acurx Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 1,591.33%. Given Acurx Pharmaceuticals' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PLUR or ACXP more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Acurx Pharmaceuticals' return on equity of -526.78% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Acurx Pharmaceuticals N/A -526.78%-223.78% Does the media favor PLUR or ACXP? In the previous week, Pluri and Pluri both had 2 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 0.94 beat Pluri's score of 0.62 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in PLUR or ACXP? 16.6% of Pluri shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, PLUR or ACXP? Pluri has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. SummaryAcurx Pharmaceuticals beats Pluri on 8 of the 12 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.67M$2.98B$5.60B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-0.6820.5827.9620.25Price / SalesN/A291.32429.2099.14Price / CashN/A42.8637.4658.16Price / Book15.777.638.045.49Net Income-$14.10M-$55.05M$3.18B$250.27M7 Day Performance-3.47%8.39%3.63%4.75%1 Month Performance43.29%5.35%4.04%7.64%1 Year Performance-79.52%1.95%29.56%16.34% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.5779 of 5 stars$0.47-5.2%$8.00+1,591.3%-79.4%$14.67MN/A-0.683PLURPluri3.411 of 5 stars$5.79+0.2%$12.00+107.3%-3.6%$45.28M$330K-1.05150Positive NewsGap DownPRLDPrelude Therapeutics3.7393 of 5 stars$0.81+1.6%$4.50+457.8%-79.5%$44.82M$7M-0.48120MURAMural Oncology3.0813 of 5 stars$2.48-3.9%$12.00+383.9%-25.4%$44.55MN/A-0.32119ATNMActinium Pharmaceuticals2.8264 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230News CoveragePositive NewsSCLXScilex2.5558 of 5 stars$6.25-1.7%$455.00+7,180.0%-90.6%$44.21M$50.71M-0.2280Positive NewsGRCEGrace Therapeutics2.567 of 5 stars$3.00-4.2%$12.00+300.0%N/A$43.28MN/A-3.37N/AGap DownXCURExicure1.4978 of 5 stars$6.47-4.6%N/A+2,115.8%$42.83M$500K-1.6950ACRVAcrivon Therapeutics3.9692 of 5 stars$1.25-3.1%$17.71+1,317.1%-83.3%$40.45MN/A-0.5658Positive NewsPEPGPepGen3.1137 of 5 stars$1.11-9.0%$7.67+590.7%-92.7%$39.92MN/A-0.3530STTKShattuck Labs3.7114 of 5 stars$0.77-7.4%$7.50+871.5%-79.9%$39.92M$5.72M-0.56100Positive News Related Companies and Tools Related Companies Pluri Alternatives Prelude Therapeutics Alternatives Mural Oncology Alternatives Actinium Pharmaceuticals Alternatives Scilex Alternatives Grace Therapeutics Alternatives Exicure Alternatives Acrivon Therapeutics Alternatives PepGen Alternatives Shattuck Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACXP Stock Alerts